JP5765937B2 - 小児腫瘍の治療 - Google Patents

小児腫瘍の治療 Download PDF

Info

Publication number
JP5765937B2
JP5765937B2 JP2010518590A JP2010518590A JP5765937B2 JP 5765937 B2 JP5765937 B2 JP 5765937B2 JP 2010518590 A JP2010518590 A JP 2010518590A JP 2010518590 A JP2010518590 A JP 2010518590A JP 5765937 B2 JP5765937 B2 JP 5765937B2
Authority
JP
Japan
Prior art keywords
tumor
treatment
tumors
childhood
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010518590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534699A (ja
JP2010534699A5 (https=
Inventor
クラウディオ・ピサーノ
ロレダーナ・ヴェッシ
パオロ・カルミナティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2010534699A publication Critical patent/JP2010534699A/ja
Publication of JP2010534699A5 publication Critical patent/JP2010534699A5/ja
Application granted granted Critical
Publication of JP5765937B2 publication Critical patent/JP5765937B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010518590A 2007-08-01 2008-07-03 小児腫瘍の治療 Expired - Fee Related JP5765937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07113603.0 2007-08-01
EP07113603 2007-08-01
PCT/EP2008/058601 WO2009015981A2 (en) 2007-08-01 2008-07-03 Treatment of pediatric tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014042649A Division JP2014111653A (ja) 2007-08-01 2014-03-05 小児腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2010534699A JP2010534699A (ja) 2010-11-11
JP2010534699A5 JP2010534699A5 (https=) 2011-08-04
JP5765937B2 true JP5765937B2 (ja) 2015-08-19

Family

ID=38799381

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010518590A Expired - Fee Related JP5765937B2 (ja) 2007-08-01 2008-07-03 小児腫瘍の治療
JP2014042649A Ceased JP2014111653A (ja) 2007-08-01 2014-03-05 小児腫瘍の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014042649A Ceased JP2014111653A (ja) 2007-08-01 2014-03-05 小児腫瘍の治療

Country Status (11)

Country Link
US (1) US8829021B2 (https=)
EP (1) EP2182951A2 (https=)
JP (2) JP5765937B2 (https=)
KR (1) KR20100051837A (https=)
CN (1) CN101784277A (https=)
BR (1) BRPI0815051A2 (https=)
CA (1) CA2694389C (https=)
EA (1) EA015933B1 (https=)
MX (1) MX2010001084A (https=)
SG (1) SG183010A1 (https=)
WO (1) WO2009015981A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040263T2 (hu) 2012-10-29 2019-02-28 Arizona Board Of Regents On Behalf Of Univ Of Arizona Prediktív markerek poliamin-inhibitor rákterápiákhoz
WO2015195120A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
CA2976106A1 (en) 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
MA43114A (fr) 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
CN114096240A (zh) 2019-05-17 2022-02-25 癌症预防制药股份有限公司 用于治疗家族性腺瘤性息肉病的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977B1 (en) * 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
PL1962850T3 (pl) 2005-12-21 2012-07-31 Sigma Tau Ind Farmaceuti Leczenie lekoopornych nowotworów
US8853233B2 (en) 2007-02-13 2014-10-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives

Also Published As

Publication number Publication date
US8829021B2 (en) 2014-09-09
WO2009015981A3 (en) 2009-09-03
CN101784277A (zh) 2010-07-21
JP2010534699A (ja) 2010-11-11
JP2014111653A (ja) 2014-06-19
SG183010A1 (en) 2012-08-30
EP2182951A2 (en) 2010-05-12
EA015933B1 (ru) 2011-12-30
KR20100051837A (ko) 2010-05-18
BRPI0815051A2 (pt) 2015-02-10
MX2010001084A (es) 2010-03-25
WO2009015981A2 (en) 2009-02-05
AU2008282024A1 (en) 2009-02-05
CA2694389A1 (en) 2009-02-05
US20100197718A1 (en) 2010-08-05
EA201070193A1 (ru) 2010-06-30
CA2694389C (en) 2016-01-19

Similar Documents

Publication Publication Date Title
Chen et al. A core–shell structure QRu-PLGA-RES-DS NP nanocomposite with photothermal response-induced M2 macrophage polarization for rheumatoid arthritis therapy
US8481553B2 (en) Antimetastatic compounds
US20150087687A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2004080462A1 (ja) c-Kitキナーゼ阻害剤
RS66238B1 (sr) Hiralni diaril makrocikl i njegova primena u lečenju karcinoma
JP6570042B2 (ja) 官能化ベンゾピラン化合物およびその使用
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
JP2014111653A (ja) 小児腫瘍の治療
TW202128174A (zh) 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
US20230277522A9 (en) Methods for treating vascular malformations
ES2935705T3 (es) Un ligando del receptor GABA A
TWI891650B (zh) 治療血管畸形之方法
AU2008282024B2 (en) Treatment of pediatric tumors
US20210137898A1 (en) Methods to treat gliomas using a stat3 inhibitor
US8853233B2 (en) Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
HK1142810A (en) Treatment of pediatric tumors
CN102633668B (zh) 化合物在转录因子失调相关疾病的治疗药物中的应用
Xu et al. TREK-1 channel as a therapeutic target for dexmedetomidine-mediated neuroprotection in cerebral ischemia
CN103142584B (zh) 多取代5-羟基吡咯酮类化合物在制备抗肿瘤的药物中的应用
Zhang et al. Metformin-loaded into chitosan hydrogel suppresses bladder tumour growth in an orthotopic mouse model via intravesical administration
CN117999076A (zh) 一类1, 4-二氢-萘啶衍生物在治疗肿瘤中的应用
CN119013019A (zh) 用于治疗癌症的oxphos抑制剂
CN121818622A (zh) 一种吲哚碱类化合物在制备用于治疗或预防肠道疾病药物中的应用
HK40097577A (zh) 对parp抑制剂耐药的癌症的治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140305

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140320

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140523

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150616

R150 Certificate of patent or registration of utility model

Ref document number: 5765937

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees